Tandem Diabetes Care Announces Second Quarter 2019 Financial Results and Updated 2019 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Tandem Diabetes (TNDM) Tops Q2 EPS by 22c, Revenues Beat; Offers FY19 Sales Outlook Above Consensus
August 1, 2019 5:08 PM EDTTandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.03), $0.22 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $93.26 million versus the consensus estimate of $70.03 million.
In comparing the second quarter of 2019 to the same period of 2018:
Worldwide pump shipments increased 290 percent to 21,258 pumps from 5,447 pumpsSales increased 173 percent to $93.3 million from $34.1 millionOperating margin improved to negative 2 percent from negative 41 percentAdjusted EBITDA(1) improved to 13 percent of sales from negative 29 percent of salesWe shipped more pumps in... More
